Latest: Cadila to apply for clinical trials for swine flu vaccine
'No retakes in governance': P Chidambaram 'cautions' Vijay ahead of Tamil Nadu p...
OTC EC and abortion pills cause menstrual problems
News: 'Greatest captain..': CSK coach Fleming credits Dhoni for CSK's success
4,430 OPTs only in Missouri; janitorial services training: US senator reveals 'v...
Latest: Weight-loss injections deliver in real life: 4 in 10 Indians shed 10% bo...
Elon Musk’s AI company will make Grok chatbot more accessible, here’s how
'You were Usain Bolt?': Zaheer recalls fiery exchange with Ponting in 2010 Mohal...
US inflation spike: CPI jumps to 3.3% in March as Iran war lifts energy costs
Update: Why is Iran not reopening the Strait of Hormuz? Unseen dangers at sea
No renovation needed: 5 easy colour swaps for fresh, airy-feel spring home decor
Fresh DELHI: With an aim to debut vaccine for Influenza H1N1 A Virus (swine flu) in India, Cadila Pharmaceutical will seek the government's nod in two days for initiating clinical trials in this regard.
Cadila Pharmaceutical Ltd (CPL) had set up a joint venture 'CPL Biologicals Pvt Ltd' with the US-based vaccine maker Novavax for manufacturing and developing a host of vaccines, including for swine flu, in India.
"The joint venture is going to file the application with the Drug Controller General of Bharat (DCGI) in the next two days for phase-I clinical trials for swine flu vaccine," CPL Chairman and Managing Director I A Pm said.
Modi expressed confidence that Cadila would be the first Indian pharma company to debut the swine flu vaccine in The country by December.
"If we get the permission of DCGI soon, then with the advanced technology available from our partner, (we) would be able to launch it in India by December this year," Pm modi said.
With its existing facility, Cipla can produce up to one million doses of the vaccine per month, which can be scaled up to two million doses, Modi said.
"Novavax has already received permission for clinical trials from the US Federal Drug Administration and if we get it soon, we can simultaneously start the trials," he added.
The government has already indicated that swine flu related applications it would clear on a fast track basis and the company is hopeful of getting instant approval for it, Pm modi added.
He said to protect from swine flu pandemic, two dosages of the vaccine are required over two weeks.
The JV has already started building a facility with an estimated investment of Rs 100 crore. In the joint venture Cadila has 80 per cent stake and the remaining 20 per cent is held by Novavax.
Besides this, Cadila Pharma also holds 5.75 per cent stake in Novavax Inc US and has a position on the board of directors of the US-based company.
Your email address will not be this published. Required fields are News Today.
We hate spam as much as you do© Copyright 2026, All Rights Reserved
